No Data
No Data
Express News | Imunon Inc: Expects Topline Results by End of July
Express News | Imunon Announces Database Lock for Phase 2 Ovation 2 Study With Imnn-001 in Advanced Ovarian Cancer
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study With IMNN-001 in Advanced Ovarian Cancer
PDF Version Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line TreatmentExpects topline results by the end of JulyLAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) --
IMUNON Gains on Test News
Express News | First Participants Vaccinated in Imunon’s Imnn-101 Phase 1 Clinical Trial
First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial
PDF Version DNA vaccine proof-of-concept study expected to demonstrate an "mRNA better" platformLAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-st
No Data